Analysis of thromboembolic events in head and neck cancer patients who underwent concurrent chemoradiotherapy with cisplatin
Hundo CHO; Jin-Hyuk CHOI; Seok-Yun KANG; Hyun-Woo LEE; Yong-Won CHOI; Tae-Hwan KIM; Mi-Sun AHN; Chul-Ho KIM; Yoo-Seob SHIN; Jeon-Yeob JANG; Young-Taek OH; Jaesung HEO; Seung-Soo SHEEN.
The Korean Journal of Internal Medicine
; : 653-659, 2022.
Artículo
en Inglés
| WPRIM | ID: wpr-927019
Background/Aims@#The study investigated the incidence of thromboembolic events (TEE) in head and neck (H&N) cancer patients who received concurrent chemoradiotherapy (CCRT) with cisplatin, and analyzed the factors affecting TEE occurrence @*Methods@#Two hundred and fifty-seven patients who started CCRT with cisplatin for H&N cancer from January 2005 to December 2019 were analyzed. @*Results@#TEE occurred in five patients, an incidence rate of 1.9%. The 2-, 4-, and 6-month cumulative incidences of TEE were 0.8%, 1.6%, and 1.9%, respectively. Khorana score was the only factor associated with TEE occurrence (p = 0.010). @*Conclusions@#The incidence of TEE in H&N cancer patients who underwent CCRT with cisplatin was relatively low when compared to other types of cancer. However, patients with a high Khorana score require more careful surveillance for possible TEE occurrence.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados